Shopping Cart 0
Cart Subtotal
USD 0

Laboratoires Pierre Fabre SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company's products address the full spectrum of health care needs from pathologies such as cancer or atopical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands which include Derma, Galenic Klorane, Avene, Ducray, Rene Furterer, and others. Pierre Fabre is headquartered in Ile-de-France, France.

Laboratoires Pierre Fabre SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17

Pierre Fabre Acquires Desogestrel from Helm Medical 18

Partnerships 19

Pierre Fabre Enters into Distribution Agreement with Medinova 19

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20

Pierre Fabre Expands Agreement with Roche for W0101 21

Pierre Fabre Enters into Agreement with MEME Cosmetics 22

Institut Curie Enters into Agreement with Pierre Fabre 23

Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24

Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25

Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26

Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27

Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28

Evotec Partners with Pierre Fabre Labs 29

Pierre Fabre Partners with VibioSphen 30

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31

Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33

Pierre Fabre Medicament Partners with Inserm Transfert 34

Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35

Pierre Fabre Partners with Biomax Informatics 36

AbCheck Expands Research Agreement with Pierre Fabre Pharma 37

Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38

Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39

AbCheck Enters Into Research Agreement With Pierre Fabre 40

Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42

Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43

Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44

Pierre Fabre Enters into Agreement with Geiser Pharma 45

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46

Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47

ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48

Licensing Agreements 49

Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49

Substipharm Enters into Licensing Agreement with Pierre Fabre 50

Pierre Fabre Enters into Licensing Agreement with Hill Derma 51

Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52

Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53

Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54

Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55

Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57

Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58

Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59

Pierre Fabre Enters into Licensing Agreement with Lonza 60

Pierre Fabre Enters into Licensing Agreement with Lonza 61

Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62

Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63

Pierre Fabre Enters into Licensing Agreement with Medis 64

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65

Pierre Fabre Enters into Licensing Agreement with PLEURAN 66

Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67

Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68

Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69

Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71

Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72

Equity Offering 73

Pierre Fabre Invests in MEME Cosmetics 73

TargeOn Raises Funds through Private Placement of Shares 74

Asset Transactions 75

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75

Acquisition 76

Pierre Fabre Sells 6% Stake In Boiron For USD 42 Million 76

Laboratoires Pierre Fabre SA-Key Competitors 77

Laboratoires Pierre Fabre SA-Key Employees 78

Laboratoires Pierre Fabre SA-Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Affiliate 82

Recent Developments 83

Corporate Communications 83

May 04, 2018: Pierre Fabre Appoints Eric Ducournau As New Chief Executive Officer 83

Other Significant Developments 84

Jun 15, 2018: Feelcaps, to promote physical activity among cancer patients 84

Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 85

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86


List Of Figure

List of Figures

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17

Pierre Fabre Acquires Desogestrel from Helm Medical 18

Pierre Fabre Enters into Distribution Agreement with Medinova 19

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20

Pierre Fabre Expands Agreement with Roche for W0101 21

Pierre Fabre Enters into Agreement with MEME Cosmetics 22

Institut Curie Enters into Agreement with Pierre Fabre 23

Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24

Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25

Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26

Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27

Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28

Evotec Partners with Pierre Fabre Labs 29

Pierre Fabre Partners with VibioSphen 30

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31

Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33

Pierre Fabre Medicament Partners with Inserm Transfert 34

Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35

Pierre Fabre Partners with Biomax Informatics 36

AbCheck Expands Research Agreement with Pierre Fabre Pharma 37

Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38

Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39

AbCheck Enters Into Research Agreement With Pierre Fabre 40

Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42

Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43

Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44

Pierre Fabre Enters into Agreement with Geiser Pharma 45

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46

Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47

ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48

Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49

Substipharm Enters into Licensing Agreement with Pierre Fabre 50

Pierre Fabre Enters into Licensing Agreement with Hill Derma 51

Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52

Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53

Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54

Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55

Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57

Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58

Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59

Pierre Fabre Enters into Licensing Agreement with Lonza 60

Pierre Fabre Enters into Licensing Agreement with Lonza 61

Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62

Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63

Pierre Fabre Enters into Licensing Agreement with Medis 64

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65

Pierre Fabre Enters into Licensing Agreement with PLEURAN 66

Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67

Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68

Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69

Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71

Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72

Pierre Fabre Invests in MEME Cosmetics 73

TargeOn Raises Funds through Private Placement of Shares 74

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75

Pierre Fabre Sells 6% Stake In Boiron For USD 42 Million 76

Laboratoires Pierre Fabre SA, Key Competitors 77

Laboratoires Pierre Fabre SA, Key Employees 78

Laboratoires Pierre Fabre SA, Other Locations 79

Laboratoires Pierre Fabre SA, Subsidiaries 80

Laboratoires Pierre Fabre SA, Affiliate 82

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company's products address the full spectrum of health care needs from pathologies such as cancer or atopical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands which include Derma, Galenic Klorane, Avene, Ducray, Rene Furterer, and others. Pierre Fabre is headquartered in Ile-de-France, France.

Laboratoires Pierre Fabre SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17

Pierre Fabre Acquires Desogestrel from Helm Medical 18

Partnerships 19

Pierre Fabre Enters into Distribution Agreement with Medinova 19

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20

Pierre Fabre Expands Agreement with Roche for W0101 21

Pierre Fabre Enters into Agreement with MEME Cosmetics 22

Institut Curie Enters into Agreement with Pierre Fabre 23

Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24

Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25

Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26

Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27

Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28

Evotec Partners with Pierre Fabre Labs 29

Pierre Fabre Partners with VibioSphen 30

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31

Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33

Pierre Fabre Medicament Partners with Inserm Transfert 34

Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35

Pierre Fabre Partners with Biomax Informatics 36

AbCheck Expands Research Agreement with Pierre Fabre Pharma 37

Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38

Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39

AbCheck Enters Into Research Agreement With Pierre Fabre 40

Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42

Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43

Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44

Pierre Fabre Enters into Agreement with Geiser Pharma 45

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46

Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47

ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48

Licensing Agreements 49

Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49

Substipharm Enters into Licensing Agreement with Pierre Fabre 50

Pierre Fabre Enters into Licensing Agreement with Hill Derma 51

Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52

Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53

Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54

Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55

Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57

Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58

Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59

Pierre Fabre Enters into Licensing Agreement with Lonza 60

Pierre Fabre Enters into Licensing Agreement with Lonza 61

Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62

Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63

Pierre Fabre Enters into Licensing Agreement with Medis 64

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65

Pierre Fabre Enters into Licensing Agreement with PLEURAN 66

Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67

Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68

Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69

Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71

Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72

Equity Offering 73

Pierre Fabre Invests in MEME Cosmetics 73

TargeOn Raises Funds through Private Placement of Shares 74

Asset Transactions 75

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75

Acquisition 76

Pierre Fabre Sells 6% Stake In Boiron For USD 42 Million 76

Laboratoires Pierre Fabre SA-Key Competitors 77

Laboratoires Pierre Fabre SA-Key Employees 78

Laboratoires Pierre Fabre SA-Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Affiliate 82

Recent Developments 83

Corporate Communications 83

May 04, 2018: Pierre Fabre Appoints Eric Ducournau As New Chief Executive Officer 83

Other Significant Developments 84

Jun 15, 2018: Feelcaps, to promote physical activity among cancer patients 84

Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 85

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86


List Of Figure

List of Figures

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Laboratoires Pierre Fabre SA, Deals By Therapy Area, 2012 to YTD 2018 10

Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12

Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17

Pierre Fabre Acquires Desogestrel from Helm Medical 18

Pierre Fabre Enters into Distribution Agreement with Medinova 19

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20

Pierre Fabre Expands Agreement with Roche for W0101 21

Pierre Fabre Enters into Agreement with MEME Cosmetics 22

Institut Curie Enters into Agreement with Pierre Fabre 23

Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24

Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25

Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26

Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27

Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28

Evotec Partners with Pierre Fabre Labs 29

Pierre Fabre Partners with VibioSphen 30

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31

Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33

Pierre Fabre Medicament Partners with Inserm Transfert 34

Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35

Pierre Fabre Partners with Biomax Informatics 36

AbCheck Expands Research Agreement with Pierre Fabre Pharma 37

Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38

Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39

AbCheck Enters Into Research Agreement With Pierre Fabre 40

Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42

Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43

Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44

Pierre Fabre Enters into Agreement with Geiser Pharma 45

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46

Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47

ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48

Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49

Substipharm Enters into Licensing Agreement with Pierre Fabre 50

Pierre Fabre Enters into Licensing Agreement with Hill Derma 51

Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52

Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53

Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54

Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55

Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57

Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58

Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59

Pierre Fabre Enters into Licensing Agreement with Lonza 60

Pierre Fabre Enters into Licensing Agreement with Lonza 61

Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62

Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63

Pierre Fabre Enters into Licensing Agreement with Medis 64

Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65

Pierre Fabre Enters into Licensing Agreement with PLEURAN 66

Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67

Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68

Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69

Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71

Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72

Pierre Fabre Invests in MEME Cosmetics 73

TargeOn Raises Funds through Private Placement of Shares 74

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75

Pierre Fabre Sells 6% Stake In Boiron For USD 42 Million 76

Laboratoires Pierre Fabre SA, Key Competitors 77

Laboratoires Pierre Fabre SA, Key Employees 78

Laboratoires Pierre Fabre SA, Other Locations 79

Laboratoires Pierre Fabre SA, Subsidiaries 80

Laboratoires Pierre Fabre SA, Affiliate 82

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS